The GCP Perspective on Study Monitoring
|
|
- Sophie Magdalene Benson
- 5 years ago
- Views:
Transcription
1 The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1
2 Overview Monitoring Basics Who, What, Why, Where, When and How On-Site Findings 2
3 What is Monitoring? Monitoring Definition: The act of overseeing the progress of a clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, standard operating procedures (SOP s), GCP, and the applicable regulatory requirement(s). * ICH Guideline Sec
4 Why is monitoring necessary? Monitoring Purpose: (a) Verify the rights and well-being of human subjects are protected (b) Verify the reported trial data are accurate, complete and verifiable from source documents (c) Verify that the conduct of the trial is in compliance with the current protocol, GCP, and applicable regulatory agencies (i.e. CIRB, FDA) New: Develop a systematic, prioritized, risk-based approach to monitoring clinical trials. * ICH Guidance for Industry: E6 GCP Consolidated Guidance Section 5.18; ICH Integrated Addendum to ICH E6(R1) Section
5 Study monitoring will keep you out of trouble!! Don t drop the ball!!! 5
6 Who can be a monitor? Monitors should Be appointed by the sponsor Receive formal training and certification Have scientific and/or clinical knowledge Have qualifications documented Be familiar with the investigational product(s), protocol, Informed Consent Forms (ICFs), SOPs, GCP, and applicable regulatory requirement(s) Be detail oriented 6
7 Monitoring Procedures: Regulatory Expectations 1999 FDA Guidance: ALCOA To be acceptable the data (from clinical trials) should meet certain fundamental elements of quality whether collected or recorded electronically or on paper. Data should be Attributable, Legible, Contemporaneous, Original, and Accurate. 7
8 Who is responsible for monitoring? Sponsors Sponsors are responsible for ensuring proper monitoring of the investigation(s) [21 CFR ] (d)selecting monitors. A sponsor shall select a monitor qualified by training and experience to monitor the progress of the investigation. [21 CFR (d)] 8
9 Who is responsible for monitoring? Site Investigators The Site Investigator (SI) is ultimately responsible for the conduct of the study at his/her site and must support all monitoring activity! 9
10 When should monitoring visits happen? In general, there is a need for on-site monitoring before, during and after the trial has ended. Frequency based on objective, enrollment rate, complexity, blinding, size, endpoints and funding Additionally, sponsors may choose remote and/or centralized monitoring during the course of the trial or a combination of all three. Described in Monitoring Plan (MP) for the trial ICH Guidance for Industry: E6 GCP Consolidated Guidance Section ; ICH Integrated Addendum to ICH E6(R1) Section
11 Centralized Monitoring New: Centralized monitoring is a remote evaluation of accumulating data, performed in a timely manner, supported by appropriately qualified and trained persons (e.g., data managers, biostatisticians). OFTEN ASSOCIATED WITH RISK-BASED MONITORING *FDA Guidance: Oversight of Clinical Investigations A Risk-Based Approach to Monitoring (August 2013) ICH Guidance for Industry: E6 GCP Consolidated Guidance Section ; ICH Integrated Addendum to ICH E6(R1) Section
12 Centralized Monitoring Benefits Centralized monitoring processes provide additional monitoring capabilities that can complement and reduce the extent and/or frequency of on-site monitoring and help distinguish between reliable data and potentially unreliable data by identifying high risk sites with higher data entry errors, protocol deviations and high rates of AE/SAEs. These sites can be targeted for on-site monitoring visits. 1. ICH Guidance for Industry: E6 GCP Consolidated Guidance Section ; ICH Integrated Addendum to ICH E6(R1)
13 How Centralized Monitoring Applies to Sites On site monitoring may be less frequent as a result of centralized monitoring However, data may be reviewed more frequently behind the scenes. Important Reminders: Keep up-to-date on data entry Be mindful of data entry errors Be especially mindful of protocol deviations 13
14 How many monitors? Factors to consider in determining the number of monitors include: Number of sites Number of subjects Rate of enrollment Product type drug? device? Complexity of the study Nature of the disease or condition * FDA Guideline for the Monitoring of Clinical Investigations, January
15 Monitoring Plan Monitoring Plans should answer the following questions: Who is responsible for study monitoring? How often will monitoring occur? What types of monitoring will be utilized? What will the monitoring activity look for? What tools will the monitor use? What are the procedures for reporting deficiencies? How will monitoring be documented? New: What are the critical data and processes? New: What are those aspects of the study that are not routine clinical practice and that require additional training. ICH Guidance for Industry: E6 GCP Consolidated Guidance Section ; ICH Integrated Addendum to ICH E6(R1) Section
16 Types of Monitoring Visits Pre-Study Selection Visit (PSSV) Site Initiation Visit (SIV) Interim Monitoring Visit (IMV) Remote Monitoring Visit (RMV) Close-Out Visit (COV) 16
17 Pre-Study Selection Visit (PSSV) Purpose: Make recommendations to the Sponsor on including a site for a trial. Collect information on Contact info and list of staff members who will participate in trial Assess Staff experience? Workload? Competing studies? Facilities - adequate and acceptable? Equipment is available?
18 Pre-Study Selection Visit (cont d) Discuss Protocol and study procedures Roles/Responsibilities Study Requirements Check for History of previous audits Criminal or civil investigations Assess site s potential for subject recruitment Question and answers session
19 Study Initiation Visit (SIV) Purpose: Ensure study staff understands the protocol, responsibilities and regulatory requirements Discuss Site Roles/Responsibilities Drug storage, dispensing, and accountability Protocol and Informed Consent How to record and report AEs and SAEs Recruitment schemas for enrollment
20 Study Initiation Visit (cont d) Ensure Training is complete and documented Investigator understands his/her responsibilities for electronic records Site understands data collection & query management using electronic data entry Study staff have a plan for conducting the study (ICF process/delegation of tasks?)
21 Interim Monitoring Visit (IMV) Purpose: Ensure staff is following the protocol Review: Documentation of informed consent Screening Logs Complete, accurate, legible source documents Protocol adherence Staff and IRB Regulatory documentation Investigator & staff carrying out only delegated tasks Facilities Drug accountability being maintained Site issues / resolutions *21 CFR & ICH GCP
22 Interim Monitoring Visit (cont d) Perform Subject Records Source Data Verification Ensure: Accuracy and completeness of CRF Recording of Screen fails Early withdrawals AEs/SAEs Deviations from the protocol: Missing visits / procedures noted Schedule time to meet with investigator to go over any questions, findings, etc
23 Remote Monitoring Visit (RMV) Sites send de-identified source documentation to monitor: Purpose 1. To verify data against the EDC 2. To open and close queries
24 Close-out Visit (COV) Purpose: Ensure that all final study activities are complete, answer site s final questions, and prepare site to close study with IRB. Collect outstanding study forms / logs Perform final review of study file documents Collect and/or destroy any unused or expired study drug, open containers and undispensed study drug Discuss: Timelines and strategies for completion of outstanding CRF and queries Plans for record retention Notification to the IRB that the study is closing
25 Monitoring Documentation and Reporting Monitoring Reports Sent to Sponsor Monitoring Letters Sent to Sponsor AND Site Communications should include: Date of activity and individual(s) conducting it Summary of the data or activities reviewed Description of non-compliance, potential noncompliance, data irregularities, or other deficiencies identified Description of actions taken, to be taken, and/or recommended, including the person responsible for completing actions and the anticipated date of completion
26 Monitoring Documentation and Reporting Monitoring documentation should be provided in a timely manner for review. Follow monitoring plan and Sponsor SOPs New: Reporting of centralized monitoring activities should be regular and may be independent from site visits. ICH Guidance for Industry: E6 GCP Consolidated Guidance Section ; ICH Integrated Addendum to ICH E6(R1) Section
27 Study Monitoring: On-Site Findings 27
28 28
29 29
30 30
31 Common Site Oversight Findings Delegation logs not complete Inappropriate staff members delegated tasks for which they were not trained or certified Lab reports, ECG printouts, etc., not reviewed and signed by the Site Investigator Not determining clinical significance while reviewing lab values and adverse events 31
32 Informed Consent Form Findings Subject signing invalid consent Wrong version Expired ICF Forgetting to write the correct date or time Signing on the wrong line Forgetting to initial and date required sections Missing pages 32
33 Ineligible Subjects Failed screening but test result(s) not reviewed and signed off by site investigator, subject randomized into study Protocol eligibility waivers not granted, subject randomized into the study The alternative 33
34 FDA Warning Letters 483 Clinical investigator warning letter: Failure to ensure proper monitoring of the investigation. 4. There is no documentation that the [redacted] device studies were monitored in 2002 and
35 FDA Warning Letters 483 Sponsor warning letter: Failure to possess written monitoring procedures and failure to ensure proper monitoring of the investigation [21 CFR (e) and 21 CFR ]. 35
36 THE RELEVANT STUFF 36
37 Who May Get Asked to Assist? Most staff will not become monitors, but a lot might have a role in a monitoring visit, including: Coordinators Fellows Nurses Radiologists Pharmacists Research Assistants Backup Coordinators No one person will have all of the answers. It is a group effort! 37
38 Preparing for a Monitoring Visit 38
39 Organization is Key! 39
40 Tips for Scheduling a Monitoring Visit Only schedule a monitor s visit when the coordinator is available for the duration of the visit and when the SI is available to meet, if even for 20 minutes. Book a room for the Monitor: Does the room have ample light? Internet connection? Space? Computer? This ensures the monitor is able to work efficiently and effectively. Is the location close to you in the event there are questions? Book visits with Pharmacy, GCRC, etc., as applicable to the study requirements. 40
41 Before the Monitoring Visit Ask yourself, where are the Regulatory Documents Subject Binders Source Documents Study Drug SI 41
42 Before the Monitoring Visit Institutional requirements: Have subject medical records/clinic charts available as required by your institution. If electronic medical records (i.e. EPIC), ask the monitor what is needed and have print-outs available. Set monitor up with EMR access FAR in advance (if needed) 42
43 Before the Monitoring Visit Regulatory Binders Are all logs complete and accurate (designation of responsibility, enrollment, study drug, etc.)? Do you have all appropriate updated and current regulatory documents (CVs, licenses, certifications) for staff members available? Do you have all IRB Submissions / Approvals / Correspondences filed? Do you have all manuals (Labs, MOPs, EDC, etc.) filed? 43
44 Before the Monitoring Visit Subject Binders Do you have lab reports associated with the visits reviewed by SI and filed in the subject binder? Do you have all necessary signatures available (lab reports, visit forms, AE logs, SAEs, etc.) as required by the study? Are all visits that have occurred entered into the Electronic Database BEFORE the monitor comes? Study Drug Do you have all the logs completed for study drug accountability? 44
45 During the Monitoring Visit Make yourself available during the visit for whatever questions that may arise. Take time to sit with the monitor to review, respond to queries, etc. Be nice to your study monitor!! They are there to help you, not just point out faults, site deficiencies, etc. They will help correct any errors and ensure it is not repeated. 45
46 After the Monitoring Visit Review the monitoring letter with your Site Investigator. Answer / correct any deficiencies as soon as you are able to avoid the possibility of forgetting to complete a requested task. Contact your monitor with questions and copy monitor on all query-related communications. 46
47 Does my study need monitoring? Not all studies require a monitor. Exempt studies include: No IND Non-FDA Regulated Biomarker and Sample Collection-only studies All studies should be monitored internally Visit Partners Quality Improvement website for assistance 47
48 Thank You! Questions? 48
Good Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationGood Documentation Practices. Human Subject Research. for
Good Documentation Practices for Human Subject Research Bridget M. Psicihulis, RHIA, CCRC Quality Improvement Unit Coordinator Human Research Protection Program Wheaton Franciscan Healthcare (last updated
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationCLOSE OUT VISIT REPORT (NO CRF TO MONITOR)
Date: Page: 1 of 8 CLOSE OUT VISIT REPORT (NO CRF TO MONITOR) Protocol: PI Name: PI Address: Date of Visit: Monitor(s): Other Sponsor Personnel Present: Site Personnel Present at Visit (include names and
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationConducting Monitoring Visits for Investigator-Initiated Trials (IITs)
Conducting Monitoring Visits for Investigator-Initiated Trials (IITs) Clinical Research Coordinator Society (CRCS) Forum 25 July 2014 Xia Yu Clinical Research Associate Singapore Clinical Research Institute
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationOverview ICH GCP E6(R2) Integrated Addendum
2017 Biomedical Research Alliance of New York LLC CITI Program is a division of BRANY Overview ICH GCP E6(R2) Integrated Addendum Introduction On 15 December 2016, the International Council for Harmonistion
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)
Replaces previous version 203.01: 01 July 2014 Study Start-Up SS 203.01 STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature
More informationEssential Documents It s Not Just a Binder!
Essential Documents It s Not Just a Binder! Kelly Unsworth, MS, CCRC, CIP Director of Research Education & Training Office for Human Subject Protection SCORE June 5, 2014 But What percentage of 2014 (to
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationSelf-Monitoring Tool
This form is designed for research personnel to use to assess their compliance with TTUHSC El Paso IRB policies and procedures, and federal regulations and guidance governing research with human subjects,
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationPLATELET-ORIENTED INHIBITION ISCHEMIC STROKE (POINT) MONITORING PLAN IN NEW TIA AND MINOR. Version 2.0 Updated 11 May 2017
PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) MONITORING PLAN Version 2.0 Updated 11 May 2017 Monitoring Plan Table of Contents 1.0 Introduction... 4 2.0 Purpose... 4 3.0 Review
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationQuality Assurance and Site Monitoring Visits. Introduction. Training Outline
Instructors: 2009 Web Seminar Series Quality Assurance and Site Monitoring Visits Amanda Moore and Scott Provost, M.M., M.S.W. "This training has been funded in whole or in part with Federal funds from
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More information16 STUDY OVERSIGHT Clinical Quality Management Plans
16 STUDY OVERSIGHT... 1 16.1 Clinical Quality Management Plans... 1 16.2 Site Visits by the LOC, SDMC and LC... 2 16.3 Protocol Team Oversight... 3 16.4 Oversight of Reportable Protocol Deviations... 3
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationDANA-FARBER / HARVARD CANCER CENTER POLICIES FOR HUMAN SUBJECT RESEARCH TITLE:
POLICY #: EDU-100 Page: 1 of 5 1. POLICY STATEMENT: Individuals who participate in research activities overseen by DF/HCC must satisfy specific training requirements in order to conduct human subject research.
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationAN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES
1 AN OVERVIEW OF CLINICAL STUDY TASKS AND ACTIVITIES Key Clinical Study Tasks and Activities 2 Discussion of Key Tasks and Activities 3 Development of the Clinical Protocol and Study Materials 3 Qualification
More information36 th Annual Meeting Preconference Workshop P4 Handout
36 th Annual Meeting Preconference Workshop P4 Handout Clinical Trial Management in Multicenter Trials: Collaborating for Success Meet Our Team Dixie Ecklund, RN, MSN, MBA Associate Director, University
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationIN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD
COMPLIANCE WITH ISO 14155:2011 GUIDANCE FOR ENSURING YOUR CLINICAL STUDY IS BEING DESIGNED, EXECUTED, AND MONITORED IN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD Introduction: An increasing trend
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationFDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
More informationPrepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department
AUDIT MANUAL Prepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department Original: October 2001 Revised: June 2010 American College of Radiology
More informationSite Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG
Site Qualification and Training (SQT) INFORMATION AND GUIDANCE SHEET FOR SITE SIGNATURE AND DELEGATION OF RESPONSIBILITIES LOG INFORMATION AND GUIDANCE SHEET FOR THE COMPLETION OF THE SITE SIGNATURE AND
More informationRegulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies
Regulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies DIRECTIONS: 1. The purpose of a regulatory binder is to assure that all essential elements are maintained in an organized
More informationSOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227
SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY SETTING FOR STAFF QUERIES Trust wide All staff involved in research Contact Jess Bisset, Research Operations Manager x20227 Guidance 1. Introduction In accordance
More informationGCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson
GCP: Investigator Responsibilities Susan Tebbs Nicola Kaganson Investigator Responsibilities Qualifications & agreements Resources Responsibilities to the subject Ethics The protocol The IMP & randomisation
More information12.0 Investigator Responsibilities
12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationSubject Research Records. Essential Regulatory and Source Documents. Subject Research Records. Regulatory Files
Essential Regulatory and Source Documents Phyllis Carello, BS, CCRC, CTRC Research Study Coordinator Manager Bridget Adams, MSHS, CCRA, Manager Clinical Trials Office & Investigator Support and Integration
More informationRecord or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;
TEXAS HEALTH RESOUCES Table 17-III. Record Retention Schedule Human Subject Research Records and Documents Approved by THR System Performance Council (SPC): 19 January 2010 Effective Date: October 14,
More informationClinical Trial Quality Assurance Common Findings
Clinical Trial Quality Assurance Common Findings Objectives Identify common findings found in research study reviews conducted by the CTQA Program Understand what findings require an action plan vs. a
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control
General Administration GA 104.00 STANDARD OPERATING PROCEDURE FOR Document Development and Change Control Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval:
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationRegulatory Inspections
Regulatory Inspections An Overview of Process, Observations, and Guidance for Investigators Alison Urton, Group Administrator Clive Hansen, Audit Team Leader Outline Regulatory History Health Canada Overview
More informationClinical Trial Readiness Checklist October 2014
The clinical trial readiness checklist is a tool which can help new and experienced researchers prepare for upcoming clinical studies. It is designed to be a quick reference to ensure that you have the
More informationThe Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.
The Clinical Research Center Research Practice Manual Guideline for Study Document and Data Handling RPG-08 Purpose Guideline This Guideline provides functional definitions for common data management terms;
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More information11/18/2016. UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities SESSION 4
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationSTUDY TEAM RESPONSIBILITIES ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2
ORIENTATION FOR NEW CLINICAL RESEARCH PERSONNEL MODULE 2 Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals Overall Agenda for Orientation Module 1: Introduction
More informationTraining, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan
Training, Site Selection and Human Subject Protection: Factors to Consider When Developing a Monitoring Plan Cynthia F. Kleppinger, M.D. Senior Medical Officer Office of Scientific Investigations Office
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationCTN POLICIES AND PROCEDURES GUIDE
National Drug Abuse Treatment Clinical Trials Network CTN POLICIES AND PROCEDURES GUIDE April 1, 2016 V6.0 TABLE OF CONTENTS 1.0 INTRODUCTION... 1 1.1 The Clinical Trials Network Structure: Definitions
More informationStandard Operating Procedures
Standard Operating Procedures 5.7 Site Initiation Version V1.0 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 30/09/2017 Review date 30/09/2019 DO NOT USE THIS SOP IN PRINTED FORM WITHOUT
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationSite Closedown Checklist for UoL Sponsored CTIMP Studies
Site Closedown Checklist for UoL Sponsored CTIMP Studies Site Information Site: Study Title: UoL study number: Centre name: Investigator: Date of Visit: Date of Report Date Responses due by: List of site
More informationUNC Lineberger Comprehensive Cancer Center. Data and Safety Monitoring Plan
UNC Lineberger Comprehensive Cancer Center Data and Safety Monitoring Plan Norman E. Sharpless, MD, Director P30CA-16086 Approved: September 29, 2014 Table of Contents Monitoring Progress of Trials and
More informationResearch & Development. Case Report Form SOP. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Case Report Form SOP SOP reference no: R&D GCP SOP 03 Authors: Current version number and date: J H Pacynko and J Illingworth Version 2, 01.02.18 Next review
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationONADE s Data Quality Review
ONADE s Data Quality Review Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulatory Affairs in Animal Health Seminar Kansas State University Olathe March 06, 2018 Presenter: Ana
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D
Page 1 of 8 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Data Safety and Monitoring Committee Administrative and Revision: N/A Revision Date: N/A Functional
More informationGood Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center
Good Clinical Practice Lisa de Blieck MPA CCRC Clinical Trials Coordination Center Good Clinical Practice (GCP) An international standard for the design, conduct, performance, monitoring, auditing, recording,
More informationHow to Prepare for Federal Inspections and What to Expect
How to Prepare for Federal Inspections and What to Expect Jennifer A. Graf Tufts Medical Center Tufts University Health Sciences Director of IRB Operations Originally presented at the February 2011 Society
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationLocal VA VA ORD CSP Other VA ORD. IRB of Record Registration Number: IRB Operated by: Local VA Non-local VA Academic Affiliate VHA Central IRB
ADMINISTRATIVE INFORMATION Principal Investigator: Study Coordinator: Protocol Title: Current Audit Date: Research Compliance Officer (RCO) or Designated Auditor(s): Local VA VA ORD CSP Other VA ORD Sponsor
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationSOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup Authorship Team: Leanne Quinn for Joint SOP Group on Trial Processes (viz Ian Russell, Anne Seagrove, Jemma Hughes, Yvette
More informationTufts Medical Center (Tufts MC) and Tufts University Health Sciences (TUHS) IRB Western IRB (WIRB) Submission Policy
Tufts Medical Center (Tufts MC) and Tufts University Health Sciences (TUHS) IRB Western IRB (WIRB) Submission Policy Policy/Procedure Phase II (IIa, IIb, or II), III, or IV protocols undertaken at Tufts
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationSOP: New Revised Reviewed Effective Date: 08 October Approved by : Supervisor/Manager Risk/Ethics Sr. Mgmt Committees Board/Councils
Title: Assessment of Study Feasibility Manual: RI MUHC Policies and Procedures Human Research SOPs Originating Dept/ Service: RI MUHC Division of Clinical Research SOP: New Revised Reviewed Effective Date:
More informationEMA & FDA Inspections: Site perspective. Shandukani Research Centre
EMA & FDA Inspections: Site perspective Shandukani Research Centre Why were we inspected? Pharmaceutical company applied for registration of the study drug (Phase I/II dosing studies in paediatrics) Large
More informationHarrison Clinical Research. Monitoring of Clinical Trials - Quality Management from a CRO s Perspective
Harrison Clinical Research Monitoring of Clinical Trials - Quality Management from a CRO s Perspective www.harrisonclinical.com 1 17Sep2009 Overview: Monitoring of Clinical Trials 1. Discovering and developing
More informationGCP INSPECTION CHECKLIST
(This list is not all inclusive; item may be added &/or deleted as per the Study/Site/Sponsor/Lab) I. General. Name and address of the clinical trial site Tel. No. & e- mail:. Date of Inspection. Inspection
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH
SOP #: CON-100 Page: 1 of 9 Effective Date: 2/28/17 1. POLICY STATEMENT: The research team is responsible for obtaining and documenting the informed consent of each subject who participates in research.
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More informationMANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS DOCUMENT NO.: CR010 v4.0 AUTHOR: Heather Charles ISSUE DATE: 01 September 2016 EFFECTIVE DATE: 15 September 2016 1 INTRODUCTION 1.1 The Academic
More information1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements
Information for Investigators: Headquarters, U.S. Special Operations Command Human Research Protection Office (HRPO) Human Research Protections Regulatory Requirements 1. Department of Defense (DoD) Human
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationA Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky
A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky I. Compliance with IRB and Applicable Federal Requirements A. Investigators
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More information